Literature DB >> 1964899

Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.

H Renaudin1, C Bébéar.   

Abstract

The in vitro activity of three macrolides, azithromycin, clarithromycin and erythromycin and a new fluoroquinolone, lomefloxacin, against pathogenic mycoplasma (16 to 18 strains of Mycoplasma pneumoniae, 41 to 77 strains of Mycoplasma hominis, 65 to 104 strains of Ureaplasma urealyticum) was compared. The three macrolides were highly active against Mycoplasma pneumoniae. Clarithromycin was the most active macrolide against Ureaplasma urealyticum whereas azithromycin was somewhat more active than erythromycin against Mycoplasma hominis. Lomefloxacin was moderately active against all three mycoplasma species.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1964899     DOI: 10.1007/bf01967388

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  Susceptibilities of genital mycoplasmas to the newer quinolones as determined by the agar dilution method.

Authors:  G E Kenny; T M Hooton; M C Roberts; F D Cartwright; J Hoyt
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 2.  [Methods of studying mycoplasma infections].

Authors:  C Bebear; B de Barbeyrac; C Bernet; H Renaudin
Journal:  Ann Biol Clin (Paris)       Date:  1989       Impact factor: 0.459

3.  In vitro comparison of the activity of doxycycline, tetracycline, erythromycin and a new macrolide, CP 62993, against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.

Authors:  M Rylander; H O Hallander
Journal:  Scand J Infect Dis Suppl       Date:  1988

4.  Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin.

Authors:  G H Cassell; K B Waites; M S Pate; K C Canupp; L B Duffy
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Sep-Oct       Impact factor: 2.803

5.  [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].

Authors:  H Renaudin; C Quentin; B de Barbeyrac; C Bebear
Journal:  Pathol Biol (Paris)       Date:  1988-05

6.  In vitro activity of azithromycin and erythromycin against organisms associated with bacterial vaginosis and chancroid.

Authors:  B M Jones; G R Kinghorn; B I Duerden
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

7.  In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.

Authors:  C A Benson; J Segreti; F E Beaudette; D W Hines; L J Goodman; R L Kaplan; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

8.  [Comparative activity of minocycline and doxycycline on mycoplasmas pathogenic for man].

Authors:  C Bebear; P Cantet; H Renaudin; C Quentin
Journal:  Pathol Biol (Paris)       Date:  1985-06

9.  In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.

Authors:  K B Waites; G H Cassell; K C Canupp; P B Fernandes
Journal:  Antimicrob Agents Chemother       Date:  1988-10       Impact factor: 5.191

  9 in total
  17 in total

1.  Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia.

Authors:  Hazem E Hassan; Ahmed A Othman; Natalie D Eddington; Lynn Duffy; Li Xiao; Ken B Waites; David A Kaufman; Karen D Fairchild; Michael L Terrin; Rose M Viscardi
Journal:  J Clin Pharmacol       Date:  2010-11-23       Impact factor: 3.126

2.  Neonatal Ureaplasma urealyticum colonization increases pulmonary and cerebral morbidity despite treatment with macrolide antibiotics.

Authors:  Bernhard Resch; C Gutmann; F Reiterer; J Luxner; B Urlesberger
Journal:  Infection       Date:  2015-10-30       Impact factor: 3.553

Review 3.  Azithromycin. A review of its pharmacological properties and use as 3-day therapy in respiratory tract infections.

Authors:  C J Dunn; L B Barradell
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 4.  Ureaplasma species: role in diseases of prematurity.

Authors:  Rose M Viscardi
Journal:  Clin Perinatol       Date:  2010-06       Impact factor: 3.430

5.  Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Authors:  L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

6.  Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  In vitro and in vivo activities of macrolides against Mycoplasma pneumoniae.

Authors:  K Ishida; M Kaku; K Irifune; R Mizukane; H Takemura; R Yoshida; H Tanaka; T Usui; N Suyama; K Tomono
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 8.  Ureaplasma species: role in neonatal morbidities and outcomes.

Authors:  Rose Marie Viscardi
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2013-08-19       Impact factor: 5.747

Review 9.  Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D H Peters; H A Friedel; D McTavish
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

Review 10.  Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.

Authors:  D H Peters; S P Clissold
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.